Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.

Journal:

Circulation

Published:

2026-02-13

DOI:

10.1161/circulationaha.125.077764

Affiliations:

10

Authors:

9

Go to article

Institutions	Authors	Share
Hypoxie PhysioPathologie Laboratory (HP2), France	1.833333	0.20
Alps Grenoble University Hospital (CHU Grenoble Alpes), France	1.833333	0.20
Sir Mortimer B. Davis Jewish General Hospital (SMBD JGH), Canada	1.500000	0.17
Bicêtre Hospital, France	1.000000	0.11
Marie Lannelongue Hospital, France	1.000000	0.11
University of Paris-Saclay, France	1.000000	0.11
McGill University, Canada	0.500000	0.06
Grenoble CIC-IT (CIC1406), France	0.333333	0.04

Interested in Oncology and Carcinogenesis?